Shares of Cipla Ltd . are trading over 3% lower on Friday, October 24, after the drugmaker signed an agreement with US pharma major Eli Lilly to sell Lilly's blockbuster weight-loss drug under a new brand in India.

Under the deal, Lilly will manufacture the drug, while Mumbai-headquartered Cipla will market it under the brand name Yurpeak, the companies said on Thursday.

Yurpeak will be available as a once-weekly pre-filled injector pen, similar to Lilly's Mounjaro Kwikpen, allowing healthcare providers to personalise treatment plans for patients.

The drug will come in six dose strengths, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, and will be priced the same as Mounjaro.

Lilly launched Mounjaro in India in late March for diabetes and obesity in 2.5 mg and 5 mg vials, and receiv

See Full Page